Mattke, Soeren
Jun, Hankyung
Chen, Emily
Liu, Ying
Becker, Andrew
Wallick, Christopher
Funding for this research was provided by:
Genentech, Inc., a member of the Roche Group
Article History
Received: 21 April 2023
Accepted: 11 July 2023
First Online: 22 July 2023
Declarations
:
: The study was approved by the Institutional Review Board of the University of Southern California under an expedited review process with a waiver of consent and HIPAA authorization (UP-21-00441).
: Not applicable
: Soeren Mattke serves on the board of directors of Senscio Systems and the scientific advisory board of AiCure, ALZpath, and Boston Millennia Partners. He has received consulting fees from Biogen, C2N Diagnostics, Eisai, Novartis, Novo Nordisk and Genentech/Roche. Christopher Wallick was an employee and shareholder of Genentech, Inc., a member of the Roche Group, at the time the study was conducted. The other authors report no conflicts.